Trinity Biotech regains compliance with Nasdaq

Trinity Biotech regains compliance with Nasdaq
Trinity Biotech shares soar on improved revenue outlook for HIV test
Trinity Biotech jumps 13% after Korea's MiCo acquires stake at premium
6.14MUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US8964383066
CUSIP
896438108
Sector
Healthcare
Industry
Medical Devices
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
0.30
Book Value
-3.85
Dividend Share
-
Dividend Yield
-
Earnings Share
-59.07
Wall Street Target Price
3.00
EPS Estimate Current Year
-
EPS Estimate Next Year
-1.09
EPS Estimate Current Quarter
-0.57
EPS Estimate Next Quarter
0
Most Recent Quarter
-
Revenue TTM
43,785,000
Gross Profit TTM
16,887,000
EBITDA
-8,243,000
Profit Margin
-85.36%
Return On Assets TTM
-5.72%
Return On Equity TTM
-1913.45%
Revenue Per Share TTM
2.357
Qtly Revenue Growth YOY
-5.50%
Diluted Eps TTM
-59.07
Qtly Earnings Growth YOY
-77.30%
Trailing PE
0.00
Forward PE
4
Price Sales TTM
0.1381
Price Book MRQ
5.7451
Enterprise Value Revenue
3
Enterprise Value EBITDA
-6
329.00
3.35%19.76
2.28%103.16
2.15%44.29
1.52%71.54
1.52%83.27
1.38%39.94
1.33%27.84
0.00%60.79
-1.93%82.21
-1.57%